Breast Cancer Survivors: Exercise and Raloxifene
- Determine the effects of raloxifene with or without exercise versus exercise alone on
bone reabsorption rate, bone formation rate, and bone density in women previously
treated for breast cancer.
- Determine the effects of these regimens on the quality of life of these patients.
OUTLINE: This is a randomized, placebo-controlled, multicenter study. Patients are
randomized to one of four treatment arms.
- Arm I: Patients are asked to exercise 5 days a week with instruction. Patients also
receive oral placebo once daily.
- Arm II: Patients receive oral raloxifene once daily.
- Arm III: Patients are asked to exercise as in arm I. Patients also receive oral
raloxifene once daily.
- Arm IV: Patients receive oral placebo once daily. All patients receive oral calcium
supplements once daily. Treatment continues in all arms for 24 months in the absence of
disease progression or unacceptable toxicity.
Quality of life is assessed at baseline and every 3 months during study.
PROJECTED ACCRUAL: A total of 240 patients (60 per treatment arm) will be accrued for this
Allocation: Randomized, Primary Purpose: Supportive Care
Anna Schwartz, FNP, PhD
OHSU Knight Cancer Institute
United States: Federal Government
|OHSU Knight Cancer Institute||Portland, Oregon 97239|